Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conversion from calcineurin inhibitor to belatacept in maintenance kidney transplant recipients
2012-001314-42Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of belatacept in kidney allograft rejection (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Proportion of subjects who survive with a functional graft at 24 months post randomization. Started Jun 2013; status: completed.
02
Drugs
belatacept
03
Conditions
kidney allograft rejection
Beyond the preview
Go deeper on 2012-001314-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001314-42.